Literature DB >> 2422209

Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen.

R Fox, R Sportsman, G Rhodes, J Luka, G Pearson, J Vaughan.   

Abstract

A monoclonal antibody, selected for reactivity with the Epstein-Barr virus (EBV)-encoded antigen EBNA-1, exhibited strong reactivity with the synovial lining cells in joint biopsies from 10 of 12 patients with rheumatoid arthritis (RA) and adherent cells eluted from these tissues. No staining of RA synovial membrane frozen tissue sections or eluted synovial-lining cells was obtained with monoclonal antibodies directed against other EBV-encoded antigens (anti-p160, anti-gp200/350) or with monoclonal antibodies directed against antigens encoded by cytomegalovirus, herpes simplex viruses, or human T cell leukemia virus type I. Among 12 osteoarthritis and normal synovial biopsies only rare reactive cells were noted. Characterization of the antigen(s) in RA synovium by the Western immunoblotting technique revealed a 62,000-molecular-weight (mol-wt) protein, in contrast to the 70,000-85,000-mol-wt EBNA-1 antigen found in EBV-transformed cells. The structural basis for the cross-reactivity of the RA synovial membrane 62,000-mol-wt protein and the EBNA-1 antigen appears to reside in the glycine-alanine rich region of these molecules. A rabbit antibody directed against a synthetic peptide (IR3-VI-2) derived from the glycine-alanine-rich region of EBNA-1 reacted with the 70,000-85,000-mol-wt EBNA-1 antigen in EBV-infected cells and with the 62,000-mol-wt molecule in RA synovial membrane extracts. Since strong antibody responses to EBNA-1 are known to exist in RA patients, these results suggest that immune responses to a cross-reactive antigen may play a role in the pathogenesis of RA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422209      PMCID: PMC424557          DOI: 10.1172/JCI112469

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence.

Authors:  M A Aslpaugh; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Jul-Aug

2.  Autoantibody to "intermediate filament" in infectious mononucleosis.

Authors:  E Linder; P Kurki; L C Andersson
Journal:  Clin Immunol Immunopathol       Date:  1979-12

3.  Evidence by reactivity with hybridoma antibodies for a probable myeloid origin of peripheral blood cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  H D Kay; D A Horwitz
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

4.  Antibody to the rheumatoid arthritis nuclear antigen. Its relationship to in vivo Epstein-Barr virus infection.

Authors:  M A Catalano; D A Carson; J C Niederman; P Feorino; J H Vaughan
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

5.  Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates.

Authors:  Y T Konttinen; S Reitamo; A Ranki; P Häyry; U Kankaanapää; O Wegelius
Journal:  Arthritis Rheum       Date:  1981-01

6.  Viral infections and IgM autoantibodies to cytoplasmic intermediate filaments.

Authors:  B H Toh; A Yildiz; J Sotelo; O Osung; E J Holborow; F Kanakoudi; J V Small
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

Authors:  P Stastny
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

8.  Multiple, heart-cross-reactive epitopes of streptococcal M proteins.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

9.  In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects.

Authors:  L Slaughter; D A Carson; F C Jensen; T L Holbrook; J H Vaughan
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. A comparison.

Authors:  E L Reinherz; L Moretta; M Roper; J M Breard; M C Mingari; M D Cooper; S F Schlossman
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

View more
  23 in total

1.  Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

Authors:  M Yamazaki; R Kitamura; S Kusano; H Eda; S Sato; M Okawa-Takatsuji; S Aotsuka; K Yanagi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Antigenic mimicry of a human cellular polypeptide by Mycoplasma hyorhinis.

Authors:  P D Fernsten; K W Pekny; J R Harper; L E Walker
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

3.  Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women.

Authors:  Barbara L Goldstein; Lori B Chibnik; Elizabeth W Karlson; Karen H Costenbader
Journal:  Autoimmunity       Date:  2011-10-20       Impact factor: 2.815

4.  Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis.

Authors:  M Musiani; M Zerbini; S Ferri; M Plazzi; G Gentilomi; M La Placa
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

5.  Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1.

Authors:  P J Venables; T Pawlowski; P A Mumford; C Brown; D H Crawford; R N Maini
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

6.  Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis.

Authors:  M Londei; C M Savill; A Verhoef; F Brennan; Z A Leech; V Duance; R N Maini; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 7.  Epstein-Barr virus infection and autoimmunity in rheumatoid arthritis.

Authors:  P Venables
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 8.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

9.  Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1.

Authors:  N Inoue; J Kuranari; S Harada; H Nakajima; M Ohbayashi; Y Nakamura; N Miyasaka; K Ezawa; F Ban; K Yanagi
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

10.  Epstein-Barr-Virus-Infected CD15 (Lewis X)-Positive Hodgkin-Lymphoma-Like B Cells in Patients with Rheumatoid Arthritis.

Authors:  Hirotake Inomata; Masami Takei; Hiroyuki Nakamura; Shigeyoshi Fujiwara; Hidetaka Shiraiwa; Noboru Kitamura; Shunsei Hirohata; Hiroyuki Masuda; Jin Takeuchi; Shigemasa Sawada
Journal:  Open Rheumatol J       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.